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Summary
Objective: The aim of this study was to evaluate the differentiation potential of two populations of muscle-derived cells (CD56 and CD56þ)
towards chondrogenic phenotype in alginate beads culture and to compare the effect of transforming growth factor beta 1 (TGFb1) on the
differentiation process in these populations.
Methods: Muscle CD56 and CD56þ cells were cultured in alginate beads, in a chondrogenic medium, containing or not TGFb1 (10 ng/ml).
Cultures were maintained for 3, 7, 14 or 21 days in a humidiﬁed culture incubator. At harvest, one culture of each set was ﬁxed for alcian blue
staining and aggrecan detection. The steady-state level of matrix macromolecules mRNA was assessed by real-time polymerase chain
reaction (PCR). Protein detection was performed by western-blot analysis. The binding activity of nuclear extracts to Cbfa1 DNA sequence
was also evaluated by electrophoretic mobility shift assays (EMSA).
Results: Chondrogenic differentiation of both CD56þ and CD56muscle-derived cells was improved in alginate scaffold, even without growth
factor, as suggested by increased chondrogenesis markers expression during the culture. Furthermore, TGFb1 enhanced the differentiation
process and allowed to maintain a high expression of markers of mature chondrocytes. Of importance, the combination of alginate and TGFb1
treatment resulted in a further down-regulation of collagen type I and type X, as well as Cbfa1 both expression and binding activity.
Conclusions: Thus, alginate scaffold and chondrogenic medium are sufﬁcient to lead both populations CD56þ and CD56 towards chondro-
genic differentiation. Moreover, TGFb1 enhances this process and allows to maintain the chondrogenic phenotype by inhibiting terminal
differentiation, particularly for CD56 cells.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Articular cartilage has a limited capacity for healing after
trauma and only few long-term treatments are available
today, including mosaicplasty, periosteal transplantation,
and autologous chondrocyte implantation (ACI)1e3. However,
these approaches do not result in the regeneration of a fully
functional hyaline-like cartilage. Tissue engineering is one
of the most promising new approaches to repair articular
cartilage. This process involves the use of various cell types,
ranged from undifferentiated pluripotent stem cells to well-
differentiated chondrocytes that can act as chondro-
progenitor cells2,4,5. As the limited donor-site capacity to
provide a large quantity of chondrocytes is a majoraBoth authors contributed equivalently to this work.
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1509impediment to autologous chondrocytes transplantation,
much interest has aroused with the use of mesenchymal
stem cells (MSCs) derived from bone marrow and other con-
nective tissues, which have the potential to differentiate into
chondrogenic lineage4e6. In light of its availability, skeletal
muscle is an attractive source of cells for use in cartilage tis-
sue engineering because it is the largest organ in the body
and only a minimally invasive procedure is required to harvest
the tissue viamuscle biopsy. Muscle has been extensively in-
vestigated as a potential source for isolation of pluripotent
stem cells that can differentiate into various lineages, includ-
ing myogenic, hematopoietic and osteogenic7e10. The cellu-
lar heterogeneity of skeletal muscle has been pointed out.
This diversity has been mainly described in rodent models,
the human counterpart being less studied11e16.
Myogenic commitment in human has been ascribed to
satellite cells and myoblasts, mesoangioblasts, pericytes,
myo-endothelial cells, CD34þ/CD133þ cells17e20. The
differentiation towards speciﬁc structures has been observed
in dedicated media (chondrocyte-, osteocyte-, and adipo-
cyte-like cells) but it was not always related to an identiﬁed
cellular progenitor11,12,15,18,21e24. These adipogenic,
1510 R. Andriamanalijaona et al.: Chondrogenesis of muscle-derived cellsosteogenic and chondrogenic differentiation abilities, how-
ever, are one hallmark of MSCs25. Concerning chondrogenic
differentiation, it has been reported that the use of mice mus-
cle-derived stem cells implantation to repair articular defects
improved the healing of the defect, by inducing hyaline carti-
lage formation with an efﬁciency equivalent to chondrocyte
transplantation26,27. However, species-speciﬁc differences
in protein functions or cascades made difﬁcult the extrapola-
tion of pathways described in rodents to the human situation.
Several methodologies have been developed to prepare
muscle cells. Explants and single ﬁber cultures allowed
studying the biology of satellite cells and of their prog-
eny12,14,28. Enzymatic dissociation followed by cell sorting,
cell cloning, immunomagnetic selection, culture in a speciﬁc
medium, allowed the preparation of human myogenic cells
in view of their clinical use15,29e36. Then, taking advantage
of a standardized large-scale methodology for preparation
of human muscle cells, some of the main cell populations
were discovered and selected from the onset of cell culture.
The two main populations identiﬁed and separated were
differentiated by expression of CD56þ, or its absence.
Human satellite cells, proliferating myoblasts, myotubes,
and ﬁbers undergoing regeneration express the CD56
antigen, equivalent to neural cell adhesion molecule (N-
CAM)11,15,32,37e40. This marker shows early speciﬁcity in
human skeletal muscle. The antigen being extracellular, the
use of antibodies linked to ﬂuorophores allows the recogni-
tion, and further sorting if any, by ﬂow cytoﬂuorimetry
(FACS)41e44. An anti-CD56 Ab (BectoneDickinson) is vali-
dated for the routine use in clinical practice, and a dedicated
kit based on immunomagnetic separation of labelled beads is
available for use in humans (Miltenyi). CD56 labelling was
used for producing and validating human myogenic cells in
the context of several clinical trials12,44,45.
The aim of this study was to determine chondrogenic
differentiation abilities of these cell populations. For this
purpose, differentiation was induced by shifting from the
myogenic growth medium towards speciﬁc conditions dedi-
cated to chondrogenesis, corresponding to alginate beads
culture with a chondrogenic medium containing dexameth-
asone and ascorbic acid. As the administration of TGFb1
can enhance cartilage healing, its inﬂuence on the differen-
tiation process was also investigated46e48. We then showed
that both subpopulations (CD56þ and CD56) have the
capacity to differentiate into chondrogenic lineage in vitro
when cultured in alginate and TGFb1 enhances the
process. However, it also delays hypertrophic markers’
synthesis, particularly concerning CD56 cells.Material and methodsSOURCE OF HUMAN MUSCLE BIOPSIESMuscle biopsies were obtained in the context of pre-clinical and clinical
trials. They were also obtained through the Tissue Bank for Research of
the French Association against Myopathies (AFM) who harvested them as
res nullus in the context of orthopaedic surgery and consisted in 0.3e1.6 g
specimen. The patients were free of muscular pathologies. Muscle biopsies
were transmitted as fresh tissue kept at 4C in Dulbecco’s Modiﬁed Eagle
Medium (DMEM, Invitrogen, Cergy-Pontoise, France) supplemented with
gentamicine (50 mg/ml, Panpharma, Fourge`res, France). One gram of fresh
muscle yields approximately 500,000 mononucleated cells.MUSCLE CELLS CULTURE SET UP AND EXPANSIONThe methodology has been previously described32,49. Brieﬂy, the fresh
biopsies were washed and ﬁnely minced using scissors. The muscle frag-
ments were digested using collagenase (Roche, Meylan, France), then
trypsineethylen diamine tetraacetic acid (EDTA) (Hyclone, Brebie`res,
France). The cell suspension was ﬁltered through 100 then 40 mm cellstrainers, pelleted and seeded (density of 2000e5000 cells/cm2). The prolifer-
ation medium contained: 80% modiﬁed custom-made modiﬁed Czapek Dox
broth (MCDB) medium (Hyclone), 20% deﬁned fetal bovine serum (FBS)
(Hyclone), gentamicine (50 mg/ml, Panpharma), 10 ng/ml human recombinant
basic ﬁbroblast growth factor (bFGF) (R&D systems, Lille, France), 106 M
dexamethasone (Merck, Fontenay-sous-Bois, France). The medium was
changed on the following day to remove tissular and cellular debris. Adherent
cells were settled for 6e8 days, then the cells were harvested by trypsinization
and expanded before reaching 80% conﬂuency. The cells were grown in this
medium for two to three passages, then shifted towards the classical MSCs
proliferation medium for one or two passages (alpha-MEM supplemented
with 20% FBS, 106 M dexamethasone, 50 mg/ml gentamicine). The cells
were used for differentiation assays on passages three to four at which they
had undergone 8e12 divisions.CYTOFLUORIMETRY CHARACTERIZATION
AND QUANTIFICATIONThe CD56 antigen (N-CAM) was used as a marker of myogenic cells32.
Muscle derived cells (MDCs) were detached by short incubation in
trypsineEDTA (5 min, 37C), resuspended in phosphate buffered saline
(PBS), and labelled for 15 min at 4C with the anti-CD56 monoclonal anti-
body, conjugated with phycoerythrin (PE) (BectoneDickinson, BD, Le
Pont-de-Claix, France). Nonspeciﬁc ﬂuorescence was determined using ap-
propriate conjugated negative isotype control (BD). Cells were washed with
PBS and suspended under 200 ml, then analyzed by FACS (Facscalibur, BD)
using the Cell Quest software. At least 104 events were analyzed. The whole
cell population was visualized using a dot plot representation [(forward scat-
ter (FSC) vs side scatter (SSC)] and the cell labelling was quantiﬁed using
the density plot representation [FSC vs ﬂuorescence axis-2 (FL2)].SELECTION OF POPULATIONS USING MAGNETIC
MICROBEADSThe CD56þ cells were positively selected using ferrite microbeads linked to
theCD56antibody (MiltenyiBiotec,Paris, France).The selectionwasperformed
according to themanufacturer instructions, except for the volume ofmicrobeads
that was twice that recommended. The buffer contained PBS (90%), human
serum albumin (LFB, Les Ulis, France; 5% in volume, 1% ﬁnal concentration)
and anticoagulant buffer ACD (Maco-Pharma, Lille, France). Brieﬂy, cells
were washed, incubated for 15 min at 4C with buffer (40% volume) and beads
(60% volume), washed with 10 times the buffer volume, centrifuged. Cells were
suspended in 500 ml buffer, loaded on the column inserted in the magnet. The
negative fraction was eluted, then the magnet was removed and the positive
fraction was eluted. Once separated, both populations were kept for differentia-
tion analysis. Cells were washed, centrifuged, counted and an aliquote was
reserved for FACS analysis of the purity. Typically, fractions enriched up to
97% were obtained using a single passage onto the LS columns.HUMAN ARTICULAR CHONDROCYTES (HACs) CULTUREArticular cartilage was obtained from femoral heads of patients undergo-
ing joint arthroplasty and then cut into small shavings before digestion
at 37C with pronase E (4 mg/ml in PBS, 45 min, SigmaeAldrich, Saint
Quentin-Fallavier, France) and Clostridium hystoliticum collagenase (1 mg/
ml, overnight, SigmaeAldrich) in DMEM containing 10% fetal calf serum
(FCS, Invitrogen Life Technologies), penicillin (100 IU/ml, Roger Bellon, Al-
fortville, France), erythromycin (100 mg/ml, Qualimed, France) and fungizone
(0.25 mg/ml, Serva, France). The cell suspension was ﬁltered through
a 70 mm-mesh nylon, centrifuged, counted and seeded at 3 104 cells/cm2
in plastic vessels. Chondrocytes were grown in DMEMþ 10% FCS and
harvested at conﬂuency.CHONDROGENIC DIFFERENTIATION CULTUREMDCs were resuspended in sodium alginate (5 106 cells/ml). Beads
were then formed by slowly dispensing droplets of the alginate cell suspen-
sion from a 22-gauge needle into a 100 mM CaCl2 solution. After washes
with 0.15 M NaCl, the beads were rinsed with a incomplete chondrogenic
medium (ICM), corresponding to DMEM with antibiotics, 100 nM dexameth-
asone, 50 mg/ml ascorbic acid-2-phosphate, 40 mg/ml proline, 1 mM sodium
pyruvate and a 1:100 dilution of Insulin Transferrin Selenium supplement
(Sigma chemical Co.). All cultures were maintained in ICM or ICM supple-
mented with rhTGFb1 (10 ng/ml, R&D system) for 21 days and the medium
was changed every 2 days. Three experiments from three different donors
were performed with both cell types.
After culture, some beads were rinsed with PBS and ﬁxed 2.5 h in 2.5%
glutaraldehyde and then, directly frozen in Tissue tech OCT medium in liquid
nitrogen. The other beads were dissolved in 55 mM sodium citrate/150 mM
NaCl and centrifuged. The pellet served for RNA and protein extractions.
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REACTION (RT-PCR)Total RNAwas extracted using Trizol reagent (Invitrogen). Twomicrograms
of DNase I-treated RNA were reverse transcribed into cDNA using the High
Capacity cDNA Archive kit (Applied Biosystems, Courtaboeuf, France). The
cDNA samples were used in real-time PCR analysis, using primers designed
with the Primer Express software, SYBR Green PCR Master Mix and the ABI
Prism 7000 SDS apparatus (Applied Biosystems), as previously described50.
18S RNA was used as a reference gene. Primer sequences used:
COLIIAþCOLIIB: Forward GGTC CTG CTG GCC CAA CT/Reverse AGG
GAC CCA TAG GAC CTT GTG; COLIIA: Forward CGG GCAG AGG TAT
AAT GAT AAG GA/Reverse GTC CCA GTG TCA CAG ACA CAG ATT; AG
GRECAN: Forward AGT GGT CAA ACT CCA GAA GTA AAT GG/Reverse
GAT GGG CCA CTT CCA ATG TCT; CBFA: Forward GTA CAG CTT TAA
GGA TTC CCT CAA TTC/Reverse TTGCTAATGCTTCGTGTTTCCA; 18
S: Forward: CGG CTA CCA CAT CCA AGG AA; Reverse: GCT GGA ATT
ACC GCG GCT. Bars represent means S.E.M. of three different samples.
Statistical signiﬁcance was assessed using the Student’s t test (n¼ 3):
*P< 0.05; **P< 0.01; ***P< 0.001.ALCIAN BLUE STAINING AND IMMUNOHISTOCHEMISTRY (IHC)Frozen beads were sectionned (10 mm). For alcian blue staining, sections
were rinsed with 0.1 N HCl to decrease the pH to 1.0, stained 10 min with
Alcian blue (Sigma) in methanol and washed twice with 0.1 N HCl to remove
nonspeciﬁc staining.
For IHC, sections were ﬁxed in 4% paraformaldehyde and pre-digested for
1 h at room temperature with chondroitinase ABC (5 U/ml in distilled water) to
allow the retrieval of glycoaminoglycan (GAG) staining. Then, sectionswere in-
cubated with anti-human aggrecan core protein (ACP) primary antibody (No-
votec, Lyon, France). Immunostaining was detected using ﬂuoresceine iso
thio cyanate (FITC)-conjugated anti-rabbit IgG secondary antibody (Tebu-
bio Santa Cruz Biotechnology, Inc., Le Perray-en-Yvelines, France). Nuclei
were counterstained with propidium iodide. Non-immune rabbit serum was
used for a negative control. At least ﬁve beads from three different cultures
were observed and only representative one is shown in ﬁgures.WESTERN-BLOT ANALYSISThe cells were lysed in radio immuno precipitation assay (RIPA) buffer
(50 mM TriseHCl lysis buffer pH 7.5 containing 1% NP-40, 150 mM NaCl,
1 mM ethylene glycol tetraacetic acid (EGTA) and protease inhibitors:
phenylmethanesulphonylﬂuoride (PMSF) (1 mM), pepstatin A (1 mg/ml),
aprotinin (1 mg/ml), and leupeptin (1 mg/ml)). After 30 min on ice, the superna-
tants were collected by centrifugation and total cellular protein amount was
determined by the Bradford’s colorimetric procedure (Bio-Rad S.A., Ivry
sur Seine, France).
Proteins (15e30 mg) were subjected to sodium dodecyl sulfate poly acryl-
amide gel electiophoresis (SDS-PAGE) in a 8% polyacrylamide gel (acrylami-
de:bis at 30:1), under reducing conditions and electrophoretically transferred to
polyvinylidene diﬂuoride membrane (NEN Life Sciences Products, Zaventem,
Belgium). For ACP detection, samples were treated with 0.5 U/ml of chondroi-
tinase ABC (Sigma), prior to western-blot analysis for 2 h at 37C. Membranes
were incubated with rabbit anti-human type II collagen, rabbit anti-human type I
collagen (Novotec), goat anti-human ACP, mouse anti-bactin (Santa Cruz Bio-
technology, Inc.) and mouse anti-human type X collagen (Sigma) primary an-
tibodies and then with the appropriate secondary antibodies. The
membranes were developed with the ECL Plus chemiluminescence detection
kit (Amersham Life Sciences, Orsay, France).ELECTROPHORETIC MOBILITY SHIFT ASSAYS (EMSA)Nuclear proteins were extracted using hypertonic buffer, as previously
described50. The protein amount was determined by the Bradford’s colori-
metric procedure (Bio-Rad S.A., Ivry sur Seine, France).
Double-stranded oligonucleotides, corresponding to Cbfa1 consensus
binding sequences, were 50-labelled with [g-32P]deoxy adenosine triphos-
phate (dATP) (NEN Life Science, Zaventem, Belgium) and T4 polynucleotide
kinase (Promega, Charbonnie`res, France). Nuclear extracts (1.5 mg) were in-
cubated with 5 fmoles of the probe, 2 speciﬁc binding buffer and 1 mg of pol-
y(dG.dC).poly(dG.dC) (Amersham Pharmacia Biotech). Samples were
fractionated (1.5 h at 150 V) in an 8% polyacrylamide gel in 0.5 TBE
(45 mM Triseborate, 1 mM Na2EDTA) and visualized by autoradiography.
ResultsALCIAN BLUE STAINING AND ACP DETECTIONUndifferentiated MDCs (day 0) or cultured during 3, 7 and
21 days in alginate beads, in ICM alone (ICM) orsupplemented with TGFb1 (T), were processed as cryostat
sections, and compared to alginate without cell.
For both populations, CD56 (Fig. 1A) and CD56þ
(Fig. 1B), the alcian blue-positive stain is correlated with
the duration of incubation and TGFb1 increased the staining
intensity. However, in CD56þ cells, the staining seems to
decrease between 7 and 21 days. Immunohistochemical
staining of ACP corroborated alcian blue staining.EXPRESSION OF CHONDROCYTE-SPECIFIC
MACROMOLECULES IN MDCsChondrogenic markers expression was analyzed by RT-
PCR and western-blot (Fig. 2). Expression in alginate beads
was compared to that of undifferentiated cells (C0), corre-
sponding to monolayer culture in expansion medium.
HACs were used as positive control of differentiated cells.
CD56 cells
Type IIA collagen mRNA was expressed at 3 days of cul-
ture and TGFb1 strongly enhanced the process (Fig. 2A1).
The mRNA level of type IIB collagen was strongly increased
by the treatment of TGFb1 at 14 and 21 days (Fig. 2A2).
The protein level of type II procollagen (250 kDa) and a1II
chain (90 kDa) was also induced by TGFb1 at 14 and 21
days, which was consistent with the RT-PCR results
(Fig. 2A3). A peak of aggrecan mRNA expression was ob-
tained at 14 days in control cells whereas TGFb1 maintains
this expression at least until 21 days (Fig. 2B1). By western-
blot analysis, we showed that ACP (210 kDa) was poorly
detected in undifferentiated cells (C0), whereas it appeared
in alginate beads cultures, and clearly enhanced by TGFb1
for each time of culture (Fig. 2B2).
CD56þ cells
In this subpopulation, type IIA collagen mRNA proﬁle
shows a peak of expression at 3 days in control cells and
at 7 days with TGFb1 treatment (Fig. 2C1). Type IIB colla-
gen transcript was particularly elevated at 21 days, with
a signiﬁcant enhancement by TGFb1 (Fig. 2C2), conﬁrmed
by western-blot (Fig. 2C3). TGFb1 progressively enhanced
ACP expression at both mRNA (Fig. 2D1) and protein level
(Fig. 2D2).EXPRESSION OF TYPE I COLLAGEN, TYPE X COLLAGEN
AND Cbfa1 AS HYPERTROPHIC CHONDROCYTE MARKERS
IN MDCsCD56 cells
Procollagen I (190 kDa) was detected in undifferentiated
cells. Its expression progressively decreased under
TGFb1 as soon as 3 days of culture (Fig. 3A1).
Type X collagen monomer (66 kDa) was inhibited by
TGFb1 (Fig. 3A2).
In order to determine whether inhibition of hypertrophic
chondrocyte markers involves Cbfa1 pathway, we
measured mRNA expression and binding activity of this
transcription factor by using the real-time PCR analysis
and EMSA. The highest expression and binding of Cbfa1
was observed at 14 days in control cells (Fig. 3B1, B2). In-
terestingly, TGFb1 strongly inhibits both expression (14
days) and binding (14 and 21 days) of the transcription
factor.
Fig. 1. Alcian blue staining of MDCs cultured in alginate beads. MDCs (CD56 and CD56þ cells), cultured in alginate beads for chondrogenic
differentiation, with or without TGFb1 (ICM¼ ICM; T¼ ICMþ TGFb1), until 21 days, were stained with alcian blue for GAG detections. Immu-
nohistochemical detection for ACP is shown in the same panel. Photographies’ magniﬁcation, alcian blue: 10; aggrecan: 60. (A) CD56
cells; (B) CD56þ cells.
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In this subpopulation as well, type I collagen is expressed
in undifferentiated cells. Even if a peak of expression is ob-
tained at 3 days, type I collagen expression decreased pro-
gressively, mostly under TGFb1 treatment.Interestingly, the a1(X) monomer was mostly detected in
undifferentiated cells (C0). Type X collagen expression
was also detected at 7 and 21 days of alginate culture
with chondrogenic medium only (Fig. 4A2). This expres-
sion was inhibited by TGFb1, particularly at 21 days of
culture.
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diminishes mRNA expression (Fig. 4B1, 21 days) and bind-
ing on Cbfa1 consensus sequence (Fig. 4B2). However,
TGFb1 produces less decrease than CD56 cells.Discussion
Recent evidences support the existence of a population
of multipotential muscle derived stem cells (MDSCs) able
to differentiate into various lineages, including myogenic,
hematopoietic, osteogenic, endothelial and neuro-
nal10,51e53. However, a limited number of studies have ex-
amined the use of muscle-derived stem cells for the
treatment of articular cartilage. That is why, we assessed
the differentiation in vitro of two subpopulations CD56þ
and CD56, towards chondrogenesis.
As evidence by the results of this study, both subpopula-
tions have the capacity for chondrogenesis in vitro, as
indicated by a positive staining for GAGs and up-regulation
of chondrogenic markers, suggesting common and shared
pathways. Our results further precise and conﬁrm the previ-
ous descriptions of chondrogenic- or osteogenic-like struc-
tures developed from unselected human muscle cellcultures15,18,22,23. Furthermore, when cultured in alginate
beads with a chondrogenic medium, MDCs behaviour
resembles to the differentiation pathway of the chondro-
osseous rudiment already observed in human BMSCs,
suggesting that CD56þ and CD56 cells, like BMSCs,
are capable of undergoing a process reminiscent of endo-
chondral ossiﬁcation, and could be considered as chon-
dro-progenitor cells54. Consequently, on the basis of our
data, we were able to deﬁne three stages in the process
of differentiation as the cells accumulate different elements
of the new extracellular matrix. In the stage I, in early differ-
entiated cells (prechondrocytes) there was type I and type X
collagens expression. During stage II (chondrocyte matura-
tion), type II collagen increased, aggrecan was enhanced,
while type I collagen decreased. Finally, type I and type X
collagens are newly synthesized, representing stage III,
where cells become pre-hypertrophic.
In most studies, neither type II nor type X collagen,
a major product of hypertrophic chondrocyte was detected
in MSCs. However, previous reports, performed on MSCs
from human bone marrow, have shown the presence of
type X collagen in undifferentiated cells as well as its
induction prior that of type II collagen when cells under-
went chondrogenesis5,55. Here, we detected them in
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Fig. 4. Expression of hypertrophic markers in CD56þ cells. CD56þ cells were cultured for differentiation as described in Material and methods
during 3, 7 and 21 days in chondrogenic medium (ICM, ) supplemented or not with 10 ng/ml TGFb1 (T,-). (A) Protein extracts from undif-
ferentiated cells (C0), from cells cultured in alginate beads and from HACs were analyzed by western-blot. Membranes were incubated with
antibody directed towards human type I (A1) and type X (A2) collagen. (B1) Cbfa1 mRNA was analyzed by real-time PCR. (B2) Nuclear ex-
tracts from undifferentiated cells or cells cultured in alginate beads during 3, 7, 14 and 21 days were used in EMSA using the Cbfa1 consensus
sequence as a probe. Nuclear extracts from cells cultured 14 days in chondrogenic medium were used for DNA competition study using an
excess of Cbfa1 consensus unlabeled probe (100-fold).
1515Osteoarthritis and Cartilage Vol. 16, No. 12both undifferentiated CD56 and CD56þ cells. MDCs
were initially expanded in a proliferating medium contain-
ing bFGF, which is widely known to induce type X colla-
gen in several cell types including MCSs. This is
probably the reason why type X collagen is present in un-
differentiated cells.
Type II procollagen is expressed in two splice forms. One
of them, type IIA procollagen, which contains an additional
69 amino acid cysteine-rich domain, is present in human
prechondrogenic and newly formed cartilage tissues56,57.
We thus think that both types of undifferentiated MDCs,
CD56þ and CD56, expressed procollagen IIA and could
be considered as prechondrogenic precursors. We can
also suppose that chondrocytic cells differentiated from
CD56 and CD56þ cells express type IIA procollagen
and are immature until a marked reduction of type I procol-
lagen synthesis occurs. Then, prechondrocytes differentiate
into mature chondrocytes and the mRNA splice form
switches from type IIA to IIB procollagen, as demonstrated
in other reports56. However, the use of an antibody speciﬁc
to type IIA procollagen N-terminal propeptide would be
necessary to exclude the presence of type IIA procollagen
protein at 14 and 21 days of MDCs alginate culture.As evidenced by the results of this study, culture medium
conditions and growth factors are essential to chondrogenic
differentiation of MDCs. Of note, the proliferation media
used in the present study contained dexamethasone from
the onset of culture, which may promote the differentiation
pathway. When cells were cultured in alginate with ICM,
the synthesis of indicators of chondrogenesis increased
signiﬁcantly. 3-D alginate beads culture has become a rele-
vant model for maintaining chondrocyte phenotype and to
study their response to cytokines58,59. Similarly, human
MSCs encapsulated in alginate have been shown to
undergo chondrogenic differentiation and could be used
for in vivo application48,60. Here, we demonstrate that algi-
nate culture of MDCs without TGFb1 addition, led them
towards chondrogenesis probably due to dexamethasone
and sodium ascorbate, as also evidenced in a previous
study by in vivo injection of differentiated MDCs in rat27.
Sodium ascorbate can modulate chondrocyte growth and
differentiation inmonolayer cultures, by increasing type II col-
lagen expression61,62. This involvement in our system to in-
duce chondrogenic markers’ synthesis is suggested.
However, we also found that alginate culturewith ICMonly in-
duced increased levels of type I and typeXcollagensproteins
1516 R. Andriamanalijaona et al.: Chondrogenesis of muscle-derived cellsat 21 days, what could be attributed to sodium ascorbate.
Indeed, previous reports have demonstrated that high con-
centration of ascorbate can lead to terminal differentiation,
with correlated increase of type X collagen synthesis63,64.
To further investigate the regulation of type X collagen
transcription in our culture system, we analyzed the DNA-
binding activity of nuclear proteins to a Cbfa1 consensus
sequence. Indeed, among the few transcriptional determi-
nants specifying hypertrophic chondrocyte-speciﬁc type X
collagen expression which have been identiﬁed to date,
the runt domain transcription factor Runx2/Cbfa1 is one of
the most important. Several Runx2 modulated target genes
have been found in osteoblastic and chondrocytic
cells65e70. Among them, Runx2 can directly transactivate
Col10a1 promoter, both in vitro and in vivo, through putative
Runx2 binding sites71. Moreover, the location of these sites
in the distal promoter is in agreement with the presence of
positive regulatory elements in the corresponding 50 posi-
tions of the human promoter72. Runx2 is also required for
differentiation of MSC into the osteoblast lineage73. Indeed,
Runx2-null mice do not have bone and, accordingly, Runx2
has been demonstrated to transactivate genes highly
expressed in osteoblasts, including osteocalcin and type I
collagen74. Furthermore, the Runx2/Cbfa1 pathway would
be involved in the differentiation process leading from
myogenesis to osteogenesis75. In our study, proteins bind-
ing activity on Runx2 consensus binding sequence was
found up-regulated in untreated cells, suggesting a potential
role of Runx2 as inducer of type I and type X collagens
expression in MDCs cultured in control conditions.
Therefore, combination of alginate and appropriate
medium was found sufﬁcient to induce chondrogenesis of
CD56 MDCs but could also lead to terminal differentiation.
Using TGFb1, we further conﬁrm its importance not only
in enhancing the chondrogenesis, but also in maintaining
the chondrogenic phenotype. TGFb1 is known to play criti-
cal roles in the regulation of chondrogenic events during
embryonic skeletal development and to stimulate chondro-
genesis of MSCs46e49,76. For both cell types studied, we
showed that TGFb1 enhances GAGs deposition, aggrecan
and type II collagen synthesis. Moreover, type I and type X
collagen proteins’ synthesis was inhibited, particularly in
CD56 cells, suggesting that chondrocytes did not demon-
strate signiﬁcant hypertrophy. This data was further
supported by the inhibition of nuclear proteins binding activ-
ity on Cbfa1 consensus sequence in TGFb1-treated MDCs
at 14 and 21 days of culture, which could explain TGFb1-
induced down-regulation of type I and type X collagens
expression.
Findings concerning TGFb1 effect on MSCs are still
controversy and underline the fact that its effect on MSCs’
osteoblastic or chondrogenic differentiation depends on
culture conditions and doses used. In vitro experiments
demonstrated that its use may lead to hypertrophic differen-
tiation, with subsequent formation of inadequate tissue
instead of hyaline cartilage48,77. However, TGFb1 has
also been shown to inhibit terminal differentiation of chon-
drocytes78,79. This reinforces our conclusions that TGFb1
administration may be more effective in preserving chon-
drocyte phenotype of MDCs cultured in alginate.Conclusions
This study allows to a better understanding of chondro-
genic differentiation of selected populations from expanded
human skeletal muscle. Alginate and TGFb1 associationpromotes the transformation of CD56þ and CD56 cells
into chondrocytes. We showed that TGFb1 is important
for maintaining chondrogenic phenotype by repressing ter-
minal differentiation. This point is of interest in view of pre-
paring grafts to repair cartilage, with lower any risk of tissue
calciﬁcation after transplantation. Thus, the mesenchymal-
like behaviour of human muscle-selected cells and our
data further support that skeletal muscle may represent
a promising source of progenitor cells, which can be used
in clinical setting to improve cartilage healing. Our results
strongly suggest the usefulness of CD56 muscle-derived
stem cells for articular cartilage repair and regeneration
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